Bottom Line: A new study identified investigational medicines made available through expanded access programs for patients with life-threatening illnesses prior to approval from the U.S. Food and Drug Administration to assess the timing and duration of investigational drug availability.
Authors: Joseph S. Ross, M.D., M.H.S., of Yale University School of Medicine, New Haven, Connecticut, and coauthors
To Learn More: The full study is available on the For The Media website.
(doi:10.1001/jamanetworkopen.2018.0283)
Editor’s Note: The article contains conflict of interest and funding support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
###
Leave a Reply